Summary
Axon Enterprise, Inc. (AXON) reported a decrease in net sales for both the three-month and nine-month periods ending September 30, 2010, compared to the same periods in the prior year. The primary drivers for this decline were fewer individually significant international and federal orders, as well as constrained municipal spending due to challenging economic conditions. While overall sales decreased, the company is focusing on new product development, including its EVIDENCE.com platform, which is beginning to contribute to revenue. Despite the sales dip, the company has implemented cost-saving measures, leading to a reduction in Selling, General, and Administrative (SG&A) expenses. The company's gross margin also experienced a decline, impacted by a shift in product mix, increased costs associated with the EVIDENCE.com service, and higher indirect manufacturing expenses. Research and development expenses were significantly reduced, reflecting the completion of intensive development for certain new products in the prior year. Axon continues to maintain a strong balance sheet with ample cash and cash equivalents, and has access to a revolving credit facility, providing sufficient liquidity for its operations and strategic initiatives.
Financial Highlights
25 data points| Revenue | $21.08M |
| Cost of Revenue | $10.67M |
| Gross Profit | $10.42M |
| R&D Expenses | $1.69M |
| SG&A Expenses | $9.42M |
| Operating Income | -$725K |
| Net Income | -$2.34M |
| EPS (Basic) | $-0.04 |
| EPS (Diluted) | $-0.04 |
| Shares Outstanding (Basic) | 62.34M |
| Shares Outstanding (Diluted) | 62.34M |
Key Highlights
- 1Net sales decreased by 9.6% for the third quarter of 2010 ($21.1M vs. $23.3M in 2009) and 8.2% for the first nine months of 2010 ($64.0M vs. $69.7M in 2009).
- 2Gross margin declined significantly, with the third quarter margin falling to 49.4% from 56.9% in the prior year, impacted by increased cost of products sold.
- 3Selling, General, and Administrative (SG&A) expenses were reduced by 17.2% in the third quarter and 11.7% for the first nine months, reflecting cost containment efforts.
- 4Research and Development (R&D) expenses saw a substantial decrease of 74.7% for the third quarter and 41.7% for the first nine months, due to the completion of major development projects.
- 5Net loss improved in the third quarter to $2.3 million (from $3.2 million in 2009) and slightly decreased for the first nine months to $4.2 million (from $4.4 million in 2009).
- 6Cash and cash equivalents decreased by $5.2 million from year-end 2009 to $40.3 million as of September 30, 2010, with net cash used in operating activities for the nine-month period.
- 7The company has no outstanding debt and maintains a revolving line of credit, indicating strong liquidity and capital resources.